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Abstract 
We report the case of a patient treated with dabrafenib and trametinib (mitogen-activated 
protein kinase pathway inhibitors) for stage 3b cutaneous melanoma who developed 
bilateral uveitis. Although there have been reports of ocular side effects with this class of 
drugs, uveitis has not been previously reported to the best of our knowledge. This case 
indicates the wide range of side effects that can be seen with the newer targeted biological 
therapies. 
 © 2013 S. Karger AG, Basel 
Introduction 
Molecularly targeted therapies are potentially more specific with fewer toxic side effects 
than many traditional chemotherapeutic agents used in the treatment of cancer [1]. 
Nevertheless, they can be associated with a variety of toxicities. We report a case of a patient 
treated with dabrafenib and trametinib  [mitogen-activated protein kinase (MAP kinase) 
pathway inhibitors] for stage 3b cutaneous melanoma who developed bilateral uveitis while 
on therapy. To the best of our knowledge, although there have been reports of ocular side 
effects with this class of drugs, uveitis has not been previously reported [2]. 
 Case Rep Ophthalmol 2013;4:279–282 
DOI: 10.1159/000357060 
 
© 2013 S. Karger AG, Basel 
www.karger.com/cop 
Joshi et al.: Uveitis as a Result of MAP Kinase Pathway Inhibition 
 
 
280 
Case Report 
A 64-year-old male underwent adjuvant treatment with oral dabrafenib 150 mg b.d. and 
oral trametinib 2 mg o.d. for a cutaneous nodular ulcerating melanoma under his left breast, 
as part of the COMBI-AD clinical trial (a trial of dabrafenib and trametinib after surgery to 
remove melanoma). He previously underwent surgical resection of the tumour (Breslow 
thickness 2.15 mm, BRAF gene positive, stage 3b) and also had positive sentinel node 
biopsies. Ocular examinations form part of the protocol of this trial, owing to previous 
associations between these agents and retinal vein occlusion and central serous chorioreti-
nopathy [3]. 
At his initial screening visit, ocular examination was unremarkable, apart from an area 
of peripheral retinal degeneration in his right eye. Two weeks after starting the trial 
medications, he experienced pyrexia and malaise. His medications were temporarily stopped 
and he was started on ibuprofen; an ocular examination at this stage also proved normal. 
One week later, the decision was made to stop the trial medications permanently. However, 
he developed floaters in the left eye after a few days, and an ocular examination revealed 
vitritis in both eyes (2+ vitreous cells, 0.5+ vitreous haze), with vitreous snowballs in the left 
eye anterior to the superotemporal retinal arcade (fig. 1). His visual acuity remained 
unaffected at 6/6. Fluorescein angiography indicated early patchy choroidal hyperfluores-
cence in both eyes together with late optic disc leakage (fig. 2). 
Endogenous endophthalmitis was considered unlikely owing to the absence of focal 
chorioretinal involvement, the lack of significant immunosuppression and the absence of any 
predisposing invasive procedures within the recent past. A presumptive diagnosis of drug-
induced inflammation was made, and it was elected to observe him without additional 
treatment. Within 6 weeks, all signs of ocular inflammation had resolved without treatment 
and without sequelae.  
Discussion 
Dabrafenib and trametinib are inhibitors of the MAP kinase pathway, a pathway that 
ultimately leads to cellular proliferation. MAP kinase pathway inhibitors have been under 
investigation in the treatment of a number of tumour types, including melanoma, and the 
aim of combining several MAP kinase inhibitors in a patient is to improve response rates, to 
delay resistance and to reduce drug toxicity, since lower doses of each drug can be used [4]. 
Some drugs in this class have been associated with ocular side effects in up to 27% of 
patients [3]. The most serious reported side effect is retinal vein occlusion [5], but uveitis 
has not been previously reported to the best of our knowledge. The mechanism behind these 
ocular side effects remains unclear, but it has been suggested that MAP kinase inhibition can 
lead to an inflammatory response with consequent breakdown of the blood-retinal barrier 
[6]. This could potentially compromise ocular immune privilege, generating autoimmune 
uveitis, thus providing an explanation for the findings in our case [7, 8]. 
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Fig. 1. Fundus photographs demonstrating 0.5+ vitreous haze in both eyes associated with vitreous 
snowballs anterior to the superotemporal retinal arcade in the left eye. All findings resolved spontaneous-
ly without treatment. 
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Fig. 2. Fluorescein angiography demonstrating early patchy choroidal hyperfluorescence in a, and late 
optic disc leakage in b. 
 
